z-logo
Premium
F3‐03‐01: Disclosing ApoE genotype status to individuals at risk for Alzheimer's disease: Applying lessons learned from the reveal study to prevention treatment trials
Author(s) -
Roberts J. Scott,
Green Robert C.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.07.230
Subject(s) - disease , anxiety , apolipoprotein e , depression (economics) , clinical psychology , medicine , alzheimer's disease , randomized controlled trial , genetic testing , psychology , genetic counseling , distress , psychiatry , gerontology , genetics , biology , economics , macroeconomics
APOE-e4 carriership (MCI 41%, dementia 48%) was more frequent than in subjects with both biomarkers normal (MCI 26%, dementia 34%) but less frequent than in subjects with both biomarkers abnormal (MCI 70%, dementia 57%). Both MCI and demented subjects with SNAP had lower MMSE scores than subjects with normal biomarker scores but higher scores than subjects with both biomarkers abnormal. Conclusions: SNAP is common in subjects with MCI and dementia and is associated with age and APOE genotype. The high frequency of SNAP in elderly subjects with a clinical diagnosis of AD suggests that at high age clinical criteria may often not be specific for AD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here